Report Library

All Reports
Datamonitor Healthcare Crohn's Disease KOL Interviews

Retail Price: $599.00

*Included free with BioMedTracker Subscription - click here to log in

April 05, 2017

Datamonitor Healthcare interviewed two inflammatory bowel disease experts, one based in France and the other in Italy, to gauge their views on marketed drugs for Crohn’s disease (CD), late-stage clinical candidates, treatment challenges and unmet needs and the future treatment of CD. The drugs discussed are listed below. The two interviews were combined into a single report.

Azasan (VRX), Cimzia, Cx601 (TIG), Entocort EC (PRGO), Entyvio (TKPYY), etrolizumab (RHHBF), filgotinib (GILD), GED 0301 (CELG), Humira (ABBV), Remicade (JNJ), Stelara (JNJ), Tysabri (BIIB), Xeljanz/Xeljanz XR (PFE).

As a special offer, we are pleased to make these two KOL interviews available free of charge to Biomedtracker clients.

If you are a KOL Insight Subscriber, please access the first and second interview from our KOL Insight portal (Subscribers only).

Biomedtracker will be offering KOL Reports and Physician Pulse Surveys for purchase a la carte, or access to all reports and surveys can be purchased as a subscription to KOL Insight. For more information on KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (858) 200-2357.

For our disclosures, please read the Biomedtracker Research Standards.

Indications Covered: Crohn's Disease
Back to the top Back to the top